BioCentury
ARTICLE | Finance

Venture rounds for Icosavax, Nucleix, Vizgen, Inscripta, Metagenomi and Volastra

April 8, 2021 12:15 AM UTC

Vaccine developer Icosavax Inc. raised $100 million in a series B round led by RA Capital Management. New investors Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds and Surveyor Capital also participated alongside existing investors Qiming Venture Partners, Adams Street Partners, Sanofi Ventures and ND Capital. The company is developing computationally designed virus-like particles for infectious respiratory diseases. 

Nucleix closes $55M round
Israeli liquid biopsy play Nucleix raised $55 million in a venture round led by RA Capital with participation from new investors BlackRock, Lilly Asia Ventures, LYFE Capital and MILFAM and existing investors OrbiMed, Aurum Ventures, DSC Investment, OCI Bio Investments and Zohar Zisapel. The company’s lead product, Lung EpiCheck, is a methylation-based blood assay for the early detection of lung cancer with an anticipated 2022 launch...